On September 5, 2025, the Department of Health (DOH) issued Department Circular No. 2025-0328, officially extending the temporary suspension of Administrative Order (AO) No. 2024-0016 for an additional sixty (60) working days. AO No. 2024-0016 introduces a new schedule of fees and charges for services provided by the Food and Drug Administration (FDA).
This extension follows the initial suspension period enacted through Department Circular No. 2025-0240, which temporarily halted implementation for the same 60-day period.
To view the full document, access it via the FDA Philippines official website.
Purpose of the Extension
The suspension aims to give the FDA sufficient time to:
- Conduct further stakeholder consultations
- Address industry concerns
- Finalize internal operational adjustments required for implementation of the new fee structure
All provisions under DC No. 2025-0240 will continue to apply during this extended suspension period.
Implications to Clients
For companies and individuals availing FDA services in the Philippines:
- The previous fee structure (based on AO No. 50s. 2001 and other relevant issuances) will remain in effect during the extended 60-working-day suspension.
- There is no change in current fees until the suspension lapses and AO No. 2024-0016 is implemented.
This extension provides stakeholders with a continued grace period for financial and operational planning, especially those anticipating significant changes under the new fee schedule.
Effectivity Date
The extension takes effect on September 5, 2025 and will remain valid for 60 working days thereafter.
For clarification or assistance with FDA-related fees and services, please contact us at sales@andamanmed.com or click the button below.
